<DOC>
	<DOC>NCT02124746</DOC>
	<brief_summary>This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), polycythemia vera (PV), or essential thrombocythemia (ET), who have tolerated and achieved stable disease or better with momelotinib treatment while enrolled in a previous clinical trial.</brief_summary>
	<brief_title>Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia, Essential</mesh_term>
	<criteria>Currently enrolled in study CCL09101E, or YM387II02, or successfully completed 24 weeks of study GSUS3521672 Able to comprehend and willing to sign informed consent form Known hypersensitivity to momelotinib, its metabolites, or formulation excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Post Polycythemia Vera Myelofibrosis</keyword>
	<keyword>Post Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>blood disorders</keyword>
</DOC>